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Abstract
Whether anticoagulation management practices are associated with improved outcomes in
elderly patients with acute venous thromboembolism (VTE) is uncertain. Thus, we aimed to
examine whether practices recommended by the American College of Chest Physicians
guidelines are associated with outcomes in elderly patients with VTE. We studied 991
patients aged65 years with acute VTE in a Swiss prospective multicenter cohort study
and assessed the adherence to four management practices: parenteral anticoagulation5
days, INR2.0 for24 hours before stopping parenteral anticoagulation, early start with
vitamin K antagonists (VKA)24 hours of VTE diagnosis, and the use of low-molecular-
weight heparin (LMWH) or fondaparinux. The outcomes were all-cause mortality, VTE
recurrence, and major bleeding at 6 months, and the length of hospital stay (LOS). We used
Cox regression and lognormal survival models, adjusting for patient characteristics. Overall,
9% of patients died, 3% had VTE recurrence, and 7%major bleeding. Early start with VKA
was associated with a lower risk of major bleeding (adjusted hazard ratio 0.37, 95% CI
0.20–0.71). Early start with VKA (adjusted time ratio [TR] 0.77, 95% CI 0.69–0.86) and use
of LMWH/fondaparinux (adjusted TR 0.87, 95% CI 0.78–0.97) were associated with a
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shorter LOS. An INR2.0 for24 hours before stopping parenteral anticoagulants was
associated with a longer LOS (adjusted TR 1.2, 95% CI 1.08–1.33). In elderly patients with
VTE, the adherence to recommended anticoagulation management practices showed
mixed results. In conclusion, only early start with VKA and use of parenteral LMWH/fonda-
parinux were associated with better outcomes.
Introduction
The American College of Chest Physicians (ACCP) regularly issues methodologically rigorous,
evidence-based clinical practice guidelines on antithrombotic therapy for acute venous throm-
boembolism (VTE) [1]. In these guidelines, several anticoagulation management practices,
which have the potential to improve medical outcomes and to reduce the length of hospital
stay (LOS), are recommended [1]. These practices include the administration of parenteral
anticoagulation for5 days and the achievement of an international normalized ratio (INR)
2.0 for24 hours before stopping parenteral anticoagulation, an early start with oral vitamin
K antagonists (VKA), and the initial treatment with subcutaneous low-molecular-weight hepa-
rin (LMWH) rather than with intravenous unfractionated heparin. These practices were
shown to reduce the incidence of medical complications, such as death, recurrent VTE, major
bleeding, thrombocytopenia and infusion phlebitis, and to decrease the LOS [2–5].
However, although elderly patients have a higher incidence of VTE and VTE-related com-
plications than younger patients, elderly patients are underrepresented in prospective studies
of VTE treatment [6–8]. Moreover, to our knowledge, whether anticoagulation management
practices recommended by the ACCP guidelines are associated with improved outcomes in
elderly patients with acute VTE has never been specifically assessed. In a large, prospective
multicenter cohort study, we therefore examined the association between recommended antic-
oagulation management practices and short-term medical outcomes and LOS in elderly
patients with acute VTE.
Methods
Cohort sample
This observational study was conducted between September 2009 and March 2012 as part of
the Swiss Cohort of Elderly Patients with Venous Thromboembolism (SWITCO65+), a pro-
spective multicenter cohort study that assessed long-term medical outcomes and quality of life
in elderly patients with acute VTE. Consecutive patients aged65 years with an acute, objec-
tively confirmed VTE were identified in the inpatient and outpatient services of all five univer-
sity and four high-volume non-university hospitals in Switzerland. The management of VTE,
including type and duration of anticoagulation, was left entirely to the discretion of the manag-
ing physicians. Anticoagulation monitoring was done by primary care physicians, as it is com-
mon practice in Switzerland. A detailed description of the study methods was previously
published [9]. The Institutional Review Board at each participating study site approved the
study and patients gave written consent to participation. The approving ethic committees were
the “Commission cantonale d’éthique de la recherche sur l’être humain Vaud” (site of Lau-
sanne), “Commission cantonale d'éthique de la recherche Genève” (site of Geneva), “Kantonale
Ethikkommission Bern” (site of Bern), “Kantonale Ethikkommission Zürich” (site of Zurich),
“Ethikkommission Nordwest- und Zentralschweiz” (sites of Basel, Lucerne and Baden),
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“Ethikkommission des Kantons Thurgau” (site of Frauenfeld) and “Ethikkommission des Kan-
tons St. Gallen” (site of St. Gallen).
Baseline data collection
For all enrolled patients, trained study nurses prospectively collected baseline demographic
information (age and sex), weight, height, comorbid conditions (active cancer, recent immobi-
lization, chronic lung disease, heart failure, neurologic disease, history of major bleeding and
VTE, and date and type of VTE), vital signs, laboratory findings (hemoglobin, serum creati-
nine), concomitant antiplatelet therapy, and VTE-related treatments using standardized data
collection forms. VTE-related treatment information included the start and stop times/dates
and the generic names of parenteral anticoagulants and VKA, insertion of a vena cava filter,
systemic and catheter-based thrombolysis, and surgical thromboembolectomy.
Anticoagulation management practices
Because our patient sample was enrolled between 2009 and early 2012, we prospectively col-
lected anticoagulation management practices recommended by the 2008 version of the ACCP
guidelines [1], including (1) administration of parenteral anticoagulants for5 days; (2)
achievement of an INR2.0 for24 hours before stopping parenteral anticoagulation; (3)
start with VKA on the first treatment day (within 24 hours of VTE diagnosis); and (4) initial
treatment with subcutaneous LMWH rather than with intravenous unfractionated heparin. All
four practices received a strong recommendation (Grade 1) by the 2008 ACCP guidelines. We
defined start with VKA on the first treatment day as the start with VKA treatment within 24
hours of VTE diagnosis. Because fondaparinux is administered once daily by subcutaneous
injection, the small minority of patients who received fondaparinux as the initial treatment
were grouped together with patients who received LMWH.
Study outcomes
The study outcomes were all-cause mortality, recurrent VTE (symptomatic or fatal), and major
bleeding within six months of VTE diagnosis, as done in previous studies of VTE-related qual-
ity of care [10, 11]. We defined recurrent symptomatic VTE as acute chest pain, new or wors-
ening dyspnea or cough, acute hemoptysis, or syncope coupled with an objective diagnosis of
pulmonary embolism based on spiral computed tomography, pulmonary angiography, or
autopsy [12], or a new unilateral leg pain or swelling coupled with an objective diagnosis of
deep vein thrombosis based on ultrasonography or contrast venography [13]. Fatal recurrent
VTE was defined as death possibly or definitely related to a recurrent PE. We defined major
bleeding as fatal bleeding, bleeding in a critical site or organ (intracranial, intra-spinal, intraoc-
ular, retroperitoneal, intra-articular, pericardial, or intramuscular with compartment syn-
drome), bleeding with reduction of hemoglobin20 g/L or leading to the transfusion of2
units of packed red blood cells [14]. Among patients who developed the index VTE in the out-
patient setting and who were admitted to the hospital, we also recorded the LOS.
Follow-up included a surveillance face-to-face evaluation at three months and a telephone
interview at six months of study participation, as well as periodic reviews of the hospital charts
[9]. During each contact, study nurses interviewed patients or proxies to obtain information
about mortality, VTE recurrence, and bleeding. If a clinical event had occurred, supplemental
information was obtained by reviewing medical charts and interviewing the patient’s primary
care physician and/or family members. A committee of three blinded clinical experts adjudi-
cated these events. Final classifications were made on the basis of the full consensus of this
committee [9].
Anticoagulation Management Practices and Clinical Outcomes in Venous Thromboembolism
PLOSONE | DOI:10.1371/journal.pone.0148348 February 23, 2016 3 / 11
Statistical analyses
We presented patient baseline characteristics and the adherence to recommended anticoagula-
tion practices as numbers and percentages or medians and interquartile ranges, as appropriate.
We examined the association between anticoagulation practices and the time to death, a first
VTE recurrence and a first major bleeding within six months of the index VTE using Cox pro-
portional hazard models. For each model, we adjusted for selected variables that have previ-
ously been found to be associated with the specific outcome, i.e., short-term all-cause mortality
[15–17], major bleeding [15, 18–20], and VTE recurrence [15, 21–24]. Because anticoagulation
practices usually differ in patients who receive invasive treatments, i.e. thrombolysis, a vena
cava filter, or surgical thromboembolectomy, such patients were excluded from all analyses.
When analyzing practices pertaining to the overlap of parenteral anticoagulants and VKA
(parenteral anticoagulation for5 days, INR2.0 for24 hours, and start with VKA on the
first treatment day), we also excluded patients who received monotherapy with parenteral anti-
coagulants (e.g., patients with cancer) or VKA, no anticoagulation at all, and those in whom
the index VTE occurred under therapeutic anticoagulation. Similarly, when analyzing the use
of LMWH/fondaparinux as the initial treatment, we excluded patients with severe renal failure
(glomerular filtration rate<30 ml/min./m2) because unfractionated heparin may be the treat-
ment of choice in such patients [1].
In the subset of outpatients with VTE who were admitted to the hospital, we assessed the
association between anticoagulation practices and the LOS using a lognormal survival model,
adjusting for a broad set of patient baseline characteristics. The model yields time ratios (TR),
with a TR above 1 indicating a prolonged LOS and a TR below 1 a shortened LOS.
Given the low proportion of missing values except for arterial oxygen saturation (23%), we
assumed missing values to be normal. When we used multiple imputation for the missing val-
ues of arterial oxygen saturation, the adjusted hazard rates and the time ratio remained almost
identical. All analyses were done using Stata 13 (Stata Corporation, College Station, Texas).
Results
Study sample
Of the 1003 patients enrolled in the cohort [9], we excluded 12 patients who did not allow the
use of their data or withdrew from the study within one day, leaving a final sample of 991 ana-
lyzed patients. One patient was lost to follow up, 26 patient withdrew consent within 6 months
but were included in the analysis. The median age was 75 years, 47% of patients were women,
63% had VTE in the outpatient setting and were admitted to the hospital, 69% had symptom-
atic pulmonary embolism with or without deep vein thrombosis, 18% active cancer, and 6%
severe renal failure (Table 1). Overall, 4% (41/991) of patients received invasive treatments (30
systemic or catheter based-thrombolysis, 11 vena cava filter insertions, and/or 3 surgical
thromboembolectomy). The median duration of anticoagulation was 8 months (interquartile
range 4 to 24 months).
Adherence to recommended anticoagulation management practices
Among patients who received parenteral anticoagulation with concomitant VKA, the adher-
ence to our pre-defined anticoagulation practices was very variable (Table 2): 86% (667/774)
received parenteral anticoagulation5 days, 36% (276/774) achieved an INR2.0 for24
hours before parenteral anticoagulation was stopped, and in 54% (414/774) VKA therapy was
started within 24 hours of VTE diagnosis. Overall, 66% (589/898) of patients received LMWH
or fondaparinux as the initial parenteral anticoagulant.
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Table 1. Patient baseline characteristics (N = 991).
Characteristic Median (IQR) or n (%)a
Age, years 75 (69–81)
Female sex 463 (47)
Outpatients with VTE who were admitted to the hospital 621 (63)
Body mass index >30 kg/m2 237 (24)
Active cancerb 178 (18)
Recent immobilizationc 219 (22)
Chronic lung diseased 136 (14)
Heart failuree 115 (12)
Neurologic disease with hemiparesis, hemiplegia, or paraplegia 29 (3)
History of major bleeding 101 (10)
History of VTE 283 (29)
Clinically overt pulmonary embolism 687 (69)
Unprovoked VTEf 694 (70)
Pulse rate 110 beats/minute 88 (9)
Systolic blood pressure <100 mm Hg 35 (4)
Arterial oxygen saturation <90%g 107 (11)
Hemoglobin <130 g/L for men and <120 g/L for women 388 (39)
Creatinine >107 μmol/L 226 (23)
Severe renal failureh 55 (6)
Concomitant antiplatelet therapyi 321 (32)
Index VTE occurred under therapeutic anticoagulationj 51 (5)
Initial treatment with parenteral anticoagulants 957 (97)
LMWHk 465 (47)
Fondaparinux 158 (16)
Unfractionated heparin 333 (34)
Danaparoid 1 (0.1)
No parenteral anticoagulation 34 (3)
Systemic or catheter-based thrombolysis 30 (3)
Vena cava ﬁlter insertion 11 (1)
Surgical thrombembolectomy 3 (0.3)
Abbreviations: IQR = interquartile range; VTE = venous thromboembolism; LMWH = low-molecular-weight
heparin.
aMissing values were 0.5% for body mass index, 0.1% for history of major bleeding, 6% for hemoglobin,
8% for creatinine, 2% for pulse rate, 2% for systolic blood pressure, 23% for arterial oxygen saturation.
bChemotherapy, radiotherapy, surgery, and/or palliative care during the last 3 months.
cBed rest >72 hours, voyage in a sitting position for >6 hours, or fracture or a cast of the lower extremity
during the last 3 months.
dChronic obstructive pulmonary disease, active asthma, lung ﬁbrosis, cystic ﬁbrosis, or bronchiectasis.
eSystolic/diastolic heart failure, left/right heart failure, forward or backward heart failure, known left
ventricular ejection fraction of <40%, or acute heart failure NYHA III/IV during the last 3 months.
fOccurrence of VTE in the absence of estrogen therapy, major surgery, or immobilization during the last 3
months.
gWith or without the administration of supplemental oxygen.
hSevere renal failure deﬁned by a glomerular ﬁltration rate <30 ml/minute/m2.
iAspirin, clopidogrel, prasugrel, and/or dipyridamol.
jTherapeutic anticoagulation with vitamin K antagonists or full-dose parenteral anticoagulation.
kDalteparin, enoxaparin, or nadroparin.
doi:10.1371/journal.pone.0148348.t001
Anticoagulation Management Practices and Clinical Outcomes in Venous Thromboembolism
PLOSONE | DOI:10.1371/journal.pone.0148348 February 23, 2016 5 / 11
Association between anticoagulation management practices and
outcomes
Within six months of VTE diagnosis, 9% (85/991) of patients died, 3% (28/991) had recur-
rent VTE, and 7% (70/991) had major bleeding. Overall, 2% of patients had fatal PE (20/991)
and fatal bleeding (19/991), respectively. The median LOS was 8 days (interquartile range,
5–11 days). After adjustment, no anticoagulation practice was associated with mortality or
VTE recurrence at six months (Table 3). However, start with VKA on the first treatment day
was associated with a lower risk of major bleeding (adjusted hazard ratio [HR] 0.37, 95% con-
fidence interval [CI] 0.20–0.71) (Table 3). In patients with early vs. late start of VKA, 47% of
major bleeds occurred during the first treatment month, and 38% of bleeds occurred under
parenteral anticoagulation. The risk of major bleeding did not differ by type of parenteral
anticoagulant used (LMWH/fondaparinux vs.unfractionated heparin) or the site of treat-
ment (home vs. hospital) in these patients. The percentage of time in the therapeutic INR
range did not differ between patients with early vs. late start of VKA treatment (58 vs%. 56%;
P = 0.28).
Whereas start with VKA on the first treatment day (adjusted TR 0.77, 95% CI 0.69–0.86)
and initial treatment with LMWH or fondaparinux (adjusted TR 0.87, 95% CI 0.78–0.97) were
associated with a decreased LOS, the achievement of an INR2.0 for24 hours before stop-
ping parenteral anticoagulation was associated with an increased LOS (adjusted TR 1.20, 95%
CI 1.08–1.33) (Table 4). Patients who received parenteral anticoagulants5 days were also
more likely to have a prolonged LOS but the association failed to achieve statistical significance
(adjusted TR 1.14, 95% CI 0.99–1.32).
When analyzing practices pertaining to the overlap of parenteral anticoagulants and VKA
(parenteral anticoagulation for5 days, INR2.0 for24 hours, and start with VKA on the
first treatment day), we excluded patients who received monotherapy with parenteral anticoag-
ulants (e.g., patients with cancer) or VKA, no anticoagulation at all, and those in whom the
index VTE occurred under therapeutic anticoagulation. Overall, only 90 (51%) of 178 patients
with cancer received VKA treatment. When these patients were excluded from analysis, our
results did not change markedly.
Table 2. Adherence to anticoagulation management practices.
Anticoagulation practice n/N (%)
Parenteral AC 5 days 667/774a (86)
INR 2.0 for 24 hours before stopping parenteral AC 276/774a (36)
Start with VKA on the ﬁrst treatment day 414/774a (54)
Initial treatment with LMWH or fondaparinux 589/898b (66)
Abbreviations: AC = anticoagulation; INR = international normalized ratio; VKA = vitamin K antagonist;
LMWH = low-molecular-weight heparin.
aPatients receiving parenteral anticoagulant monotherapy (n = 122), VKA monotherapy (n = 25), no AC
(n = 9), vena cava ﬁlter insertion (n = 11), systemic or catheter-based thrombolysis (n = 30), surgical
thromboembolectomy (n = 3), or in whom the index venous thromboembolism occurred under therapeutic
AC (n = 51) were excluded. Patients could have more than one exclusion criterion.
bPatients with vena cava ﬁlter insertion (n = 11), systemic or catheter-based thrombolysis (n = 30), surgical
thromboembolectomy (n = 3), or a glomerular ﬁltration rate <30 ml/minute/m2 (n = 55) were excluded.
Patients could have more than one exclusion criterion.
doi:10.1371/journal.pone.0148348.t002
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Discussion
In our prospective multicenter cohort study of elderly patients with acute VTE, the adherence
to the four recommended anticoagulation management practices was highly variable (36–
Table 3. Associations between anticoagulation practices and clinical outcomes at 6 months.
Adherence n/N (%)
Yes No (95% CI)
Mortality Adjusted HR*
Parenteral AC 5 days 34/667 (5.1) 4/107 (3.7) 1.14 (0.39–3.27)
INR 2.0 for 24 hours before stopping parenteral AC 15/276 (5.4) 23/498 (4.6) 0.75 (0.37–1.53)
Start with VKA on the ﬁrst treatment day 11/414 (2.7) 27/360 (7.5) 0.49 (0.23–1.03)
Initial treatment with LMWH or fondaparinux 40/589 (6.8) 30/309 (9.7) 0.83 (0.51–1.34)
Recurrent venous thromboembolism Adjusted HR†
Parenteral AC 5 days 17/667 (2.5) 3/107 (2.8) 0.92 (0.27–3.14)
INR 2.0 for 24 hours before stopping parenteral AC 7/276 (2.5) 13/498 (2.6) 0.96 (0.38–2.42)
Start with VKA on the ﬁrst treatment day 8/414 (1.9) 12/360 (3.3) 0.52 (0.21–1.28)
Initial treatment with LMWH or fondaparinux 14/589 (2.4) 10/309 (3.2) 0.72 (0.32–1.62)
Major bleeding Adjusted HR‡
Parenteral AC 5 days 39/667 (5.8) 6/107 (5.6) 1.02 (0.43–2.42)
INR 2.0 for 24 hours before stopping parenteral AC 15/276 (5.4) 30/498 (6.0) 0.88 (0.47–1.64)
Start with VKA on the ﬁrst treatment day 14/414 (3.4) 31/360 (8.6) 0.37 (0.20–0.71)
Initial treatment with LMWH or fondaparinux 34/589 (5.8) 25/309 (8.1) 0.78 (0.46–1.33)
Abbreviations: AC = anticoagulation; HR = hazard ratio; CI = conﬁdence interval; INR = international normalized ratio; VKA = vitamin K antagonist;
LMWH = low-molecular-weight heparin.
*Adjusted for age, sex, active cancer, chronic lung disease, heart failure, history of major bleeding, recent immobilization, clinically overt pulmonary
embolism, pulse rate 110 beats/minute, systolic blood pressure <100 mm Hg, and arterial oxygen saturation <90%.
†Adjusted for age, cancer, history of venous thromboembolism, and type of venous thromboembolism (unprovoked vs. provoked).
‡Adjusted>Adjusted for age, cancer, history of major bleeding, clinically overt pulmonary embolism, hemoglobin level, creatinine level, and concomitant
antiplatelet therapy.
doi:10.1371/journal.pone.0148348.t003
Table 4. Association between anticoagulation practices and length of hospital stay*.
Practice performed
Yes No
Anticoagulation practice Median LOS Time ratio† (95% CI)
Parenteral AC 5 days 8.0 6.0 1.14 (0.99–1.32)
INR 2.0 for 24 hours before stopping parenteral AC 8.0 7.0 1.20 (1.08–1.33)
Start with VKA on the ﬁrst treatment day 6.0 8.0 0.77 (0.69–0.86)
Initial treatment with LMWH or fondaparinux 7.0 8.0 0.87 (0.78–0.97)
Abbreviations AC = anticoagulation; LOS = length of hospital stay; CI = conﬁdence interval; INR = international normalized ratio; LMWH = low-molecular-
weight heparin.
*Subgroup of outpatients with venous thromboembolism who were admitted to the hospital (n = 621).
†Adjusted for age, sex, body mass index, active cancer, chronic lung disease, heart failure, neurologic disease, history of major bleeding, history of
venous thromboembolism, recent immobilization, pulse rate 110 beats/minute, systolic blood pressure <100 mm Hg, arterial oxygen saturation <90%,
hemoglobin level, creatinine level, concomitant antiplatelet therapy, unprovoked venous thromboembolism, and clinically overt pulmonary embolism
doi:10.1371/journal.pone.0148348.t004
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86%). Overall, two out of four practices were associated with a lower rate of major bleeding
and/or a shorter LOS.
As expected, starting VKA on the first treatment day was associated with a reduction of the
median LOS by two days. These findings are consistent with a meta-analysis of five random-
ized controlled trials in which hospital stay was approximately four days shorter in patients
with an early start of VKA [25]. In our study, early start with VKA was also associated with a
significant decrease in major bleeding. In a prior meta-analysis, early initiation with VKA was
associated with a lower risk of minor but not major bleeding [25]. The beneficial effect of start-
ing VKA early on incidence of minor bleeding has been explained by concomitant earlier with-
drawal of heparin, which shortens the exposure to this antithrombotic agent [25]. In a
retrospective study of U.S. veterans, the administration of warfarin within one day of starting
heparin was associated with a significantly lower overall 90-day complication rate (death, VTE
recurrence, or major bleeding) [26]. However, the lower bleeding rate in patients with an early
VKA start could also be the effect of an indication bias, i.e. physicians may deliberately delay
VKA treatment in patients perceived to have a higher bleeding risk. A prior study demon-
strated that patients with an early start with VKA also had a lower risk of thrombocytopenia
and heparin-induced infusion phlebitis [4]. Overall, these results confirm that an early start of
VKA has the potential to safely reduce costly hospital days in elderly patients with VTE. The
fact that only half of patients received early VKA treatment in our study suggests that this cost-
saving anticoagulation practice is still underused in elderly patients with acute VTE.
The 2008 ACCP guidelines recommend parenteral anticoagulant treatment5 days and
the achievement an INR2.0 for24 hours before stopping parenteral anticoagulation
because randomized trials of VTE treatment often used heparin therapy for a minimum dura-
tion of five days [1, 27–29]. Moreover, there is evidence from animal studies that VKA require
several days before developing a therapeutic antithrombotic effect [30, 31]. While the adher-
ence to these anticoagulation practices was not associated with improved clinical outcomes,
both practices were associated with a 1 to 2-day increase in LOS. This does not come as a sur-
prise because physicians may be reluctant to discharge elderly patients before the 5-day course
of parenteral anticoagulation is completed and patients are successfully switched to VKA treat-
ment within the therapeutic range. Further studies should examine whether a shorter course of
parenteral anticoagulants (e.g., three days) is as effective as a 5-day course. Care organizations
that facilitate the switch from parenteral anticoagulants to VKA in the outpatient setting may
have the potential to substantially decrease the LOS.
Compared to intravenous unfractionated heparin, initial parenteral anticoagulation with
subcutaneous LMWH/fondaparinux was associated with shorter LOS because the latter treat-
ment can be given on an outpatient basis [10, 12]. In our study, the use of LMWH/fondapari-
nux reduced the median LOS by one day. A meta-analysis of randomized controlled trials
demonstrated that LMWH was associated with significantly fewer deaths (odds ratio, 0.76) and
lower rates of recurrent VTE (odds ratio, 0.68) and major bleeding (odds ratio, 0.57) [2]. While
our study did not find any association between use of LMWH/fondaparinux and clinical out-
comes, it may not have enough power to detect such an association. In our study, only about
two-thirds of elderly patients without severe renal failure received LMWH/fondaparinux.
Given its proven benefit to reduce the LOS and its potential to improve patient outcomes, the
use of parenteral anticoagulation with LMWH or fondaparinux should be encouraged in
elderly patients with acute VTE.
Our study has potential limitations. First, because new oral anticoagulants (direct thrombin
and factor Xa inhibitors) were not authorized for the treatment of acute VTE in Switzerland at
the time of patient enrollment, we could not evaluate the potential impact of these drugs on
patient outcomes. Second, we could not study the association between anticoagulation
Anticoagulation Management Practices and Clinical Outcomes in Venous Thromboembolism
PLOSONE | DOI:10.1371/journal.pone.0148348 February 23, 2016 8 / 11
practices and other clinically relevant outcomes, such as heparin-induced thrombocytopenia
or infusion phlebitis. Third, because we had only a limited number of VTE recurrences
(n = 28) during follow-up, our study may have been underpowered to detect weaker associa-
tions between anticoagulation practices and VTE recurrence. Fourth, despite extensive adjust-
ment, the observed outcome differences may be attributable to confounding related to
unmeasured severity of illness. Thus, regarding the association of early start with VKA and
lower major bleeding risk, there might be a patients selection process, where physicians tend to
start oral anticoagulation early in healthier patients who have a lower bleeding risk. Finally,
because we focused on initial anticoagulation practices, we cannot exclude the possibility that
other anticoagulation-related factors (e.g., anticoagulation quality) and treatments during fol-
low-up have influenced medical outcomes.
Conclusion
In conclusion, the adherence to recommended anticoagulation management practices showed
mixed results in elderly patients with VTE. Only early start with VKA and use of parenteral
LMWH/fondaparinux rather than unfractionated heparin were associated with better out-
comes. Given the suboptimal adherence rate of these practices and their potential clinical and
economic benefit, their implementation could be useful.
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